Lexicon Pharma CFO/COO Jeffrey Wade to depart Sep 30; Kristen Alexander named principal financial officer

LEXICON PHARMACEUTICALS, INC.

Jeffrey Wade's employment as president, COO and principal financial officer terminates Sep 30, 2024.
Wade receives salary continuation of $585k for 12 months, lump sum $175.5k, COBRA $3.7k/mo for 12 months, plus outplacement.
Wade enters 8-month consulting agreement at $3,000/month starting after termination.
Kristen Alexander, VP finance and accounting and principal accounting officer since 2021, becomes principal financial officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kristen L. Alexander

Principal Financial Officer

LXRX · LEXICON PHARMACEUTICALS, INC.

Effective: 2024-09-30
Filed: September 16, 2024, 7:59 PM ET

Effective as of the date of termination of Mr. Wade’s employment, Kristen L. Alexander will assume the function of our principal financial officer.

Departed

Jeffrey L. Wade

President and Chief Operating Officer

LXRX · LEXICON PHARMACEUTICALS, INC.

Effective: 2024-09-30
Successor: Kristen L. Alexander
Filed: September 16, 2024, 7:59 PM ET

On September 13, 2024, we and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristen L. Alexander was appointed as Principal Financial Officer at LEXICON PHARMACEUTICALS, INC..

Action: appointed
Role: Principal Financial Officer

Exact text from the filing

Effective as of the date of termination of Mr. Wade’s employment, Kristen L. Alexander will assume the function of our principal financial officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey L. Wade was terminated as President and Chief Operating Officer at LEXICON PHARMACEUTICALS, INC..

Action: terminated
Role: President and Chief Operating Officer

Exact text from the filing

On September 13, 2024, we and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.

View on SEC.gov

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-24-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.